AZ discontinues sepsis programme

Wednesday 8 August 2012

A second experimental treatment for severe sepsis, a significant area of unmet medical need, has been discontinued following the failure of a proof-of-concept trail. AstraZeneca Plc has stopped development of AZD9773, an anti-TNF-alpha antibody fragment.

Full text available to subscribers only. Click here for information on subscribing to MedNous.